KR20190021114A - Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract - Google Patents
Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract Download PDFInfo
- Publication number
- KR20190021114A KR20190021114A KR1020170106280A KR20170106280A KR20190021114A KR 20190021114 A KR20190021114 A KR 20190021114A KR 1020170106280 A KR1020170106280 A KR 1020170106280A KR 20170106280 A KR20170106280 A KR 20170106280A KR 20190021114 A KR20190021114 A KR 20190021114A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- extract
- composition
- acne
- sebum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 81
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 39
- 206010000496 acne Diseases 0.000 title claims abstract description 39
- 210000002374 sebum Anatomy 0.000 title claims abstract description 36
- 230000028327 secretion Effects 0.000 title claims abstract description 33
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 23
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 13
- 239000000419 plant extract Substances 0.000 title description 6
- 239000000284 extract Substances 0.000 claims abstract description 68
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 11
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 11
- 235000004298 Tamarindus indica Nutrition 0.000 claims abstract description 6
- 229940062013 tamarind extract Drugs 0.000 claims description 34
- 229940119485 safflower extract Drugs 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 19
- 239000006210 lotion Substances 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000004209 hair Anatomy 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000002335 preservative effect Effects 0.000 claims description 6
- 239000000516 sunscreening agent Substances 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000002781 deodorant agent Substances 0.000 claims description 4
- 239000003995 emulsifying agent Substances 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000001629 suppression Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 239000002304 perfume Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000002023 wood Substances 0.000 claims description 2
- 241000596504 Tamarindus Species 0.000 claims 1
- 238000004299 exfoliation Methods 0.000 claims 1
- 239000003009 skin protective agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 19
- 230000014509 gene expression Effects 0.000 abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 13
- 240000002657 Thymus vulgaris Species 0.000 abstract description 8
- 235000007303 Thymus vulgaris Nutrition 0.000 abstract description 7
- 239000001585 thymus vulgaris Substances 0.000 abstract description 7
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 240000004584 Tamarindus indica Species 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 4
- 230000002086 anti-sebum Effects 0.000 abstract 2
- 210000003491 skin Anatomy 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 13
- 239000008213 purified water Substances 0.000 description 12
- 108010057466 NF-kappa B Proteins 0.000 description 10
- 102000003945 NF-kappa B Human genes 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000341 volatile oil Substances 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000012046 mixed solvent Substances 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 238000013329 compounding Methods 0.000 description 5
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 5
- -1 exfoliants Substances 0.000 description 5
- 210000002510 keratinocyte Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 229940015975 1,2-hexanediol Drugs 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 3
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 244000131522 Citrus pyriformis Species 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960003473 androstanolone Drugs 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229930182478 glucoside Natural products 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 240000007436 Cananga odorata Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical class CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 235000007571 Cananga odorata Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- WYWZRNAHINYAEF-UHFFFAOYSA-N Padimate O Chemical compound CCCCC(CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003048 aphrodisiac agent Substances 0.000 description 1
- 230000002509 aphrodisiac effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- IUWVALYLNVXWKX-UHFFFAOYSA-N butamben Chemical compound CCCCOC(=O)C1=CC=C(N)C=C1 IUWVALYLNVXWKX-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000003699 hair surface Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940079988 potassium cocoyl glycinate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940083608 sodium hydroxide Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- Y10S514/857—
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물 추출물, 구체적으로 홍화, 타임, 및/또는 타마린드 추출물을 포함하는 피부 항염, 피부 피지 분비 억제용 및 여드름 개선용 조성물에 관한 것이다.The present invention relates to a composition for inhibiting skin inflammation, suppressing the secretion of skin sebum, and improving acne, which comprises a plant extract, specifically, safflower, thyme, and / or tamarind extract.
피부의 기능 중 가장 중요한 기능은 인체를 외부의 물리적화학적 요인으로부터 보호하는 것이다. 이러한 피부에는 피지선이라는 기름샘이 있으며, 여기에서 피지가 분비되어 모공을 통하여 피부표면으로 배출된다. 이렇게 배출된 피지는 피부표면에서 수분의 증발을 막고 세균으로부터 인체를 보호하는 역할을 한다. 정상적으로 이러한 피지는 피부 및 모발 표면에 지방막을 형성하여 외부의 균으로부터 우리 피부와 몸을 보호하는 항균작용을 비롯하여 자외선으로부터 피부를 보호하거나 피부를 촉촉하게 하는 등 여러 기능을 하는데, 피지선에서부터 피지 분비가 많아지거나 모공을 통과하는 과정에서 장애가 있게 되면 모공은 확대되게 된다.The most important function of the skin is to protect the body from external physical and chemical factors. This skin has an oil gland called sebaceous gland, where sebum is secreted and excreted through the pores to the skin surface. The sebum thus discharged functions to prevent the evaporation of moisture from the skin surface and to protect the human body from bacteria. Normally, these sebaceous glands form a fatty membrane on the skin and hair surface to protect the skin and body from external bacteria, as well as to protect the skin from ultraviolet rays, or to moisturize the skin. The sebaceous glands secrete sebum from the sebaceous glands When there is an increase in the number of pores or the passage of the pores, the pores are enlarged.
여드름은 털피지샘 단위의 만성 염증질환으로 면포, 구진, 고름물집, 결절 등의 다양한 병변으로 나타나며 흉터를 남기기도 한다. 여드름의 원인은 다양한 인자가 복합적으로 작용하며, 대표적인 발생요인으로 피지분비 증가, 과다각질화, 원인균(P. acnes)의 증식, 염증 반응 등이 있으며 그 외에도 유전적, 환경적 요인이 관여하는 것으로 알려져 있다.Acne is a chronic inflammatory disease of the hair follicle. It is caused by various lesions such as cotton papules, papules, blisters, nodules, and scars. The cause of acne is a combination of various factors. Typical causes of acne include increased sebum secretion, excessive keratinization, proliferation of P. acnes , inflammatory response, and other genetic and environmental factors. have.
여드름성 피부는 피지가 과다하게 분비되며, 따라서 피지 분비량은 여드름의 중증도와 밀접한 관련이 있다. 따라서 여드름은 피지선이 많이 모여 있는 얼굴, 두피, 목, 가슴, 등, 상지, 어깨 부위에 주로 발생한다.Acne skin is excessively secreted, so sebum secretion is closely related to the severity of acne. Therefore, acne is common on face, scalp, neck, chest, back, upper and shoulders where sebaceous glands are concentrated.
피부에서 제1형 5α-환원효소에 의해 디하이드로테스토스테론(dihydrotestosterone; DHT)가 증가하거나, DHT 수용체의 민감도 증가 또는 안드로겐이 증가하면 피지 분비량이 늘어난다. 이 과정에서 불포화 지방산 생합성 효소의 일종인 스테아로일-코엔자임A 불포화효소-1(stearoyl-CoA desaturase-1; SCD-1)가 전사조절부위 SRE(sterol regulatory element)에 결합하여 콜레스테롤과 지방산을 포함한 지질생성을 조절하게 된다. 피부에서 피지가 원활히 배출되지 못하면 모공의 공기 순환을 차단하여 혐기성 세균인 혐기세균인 프로박테리움 아크네(P. acnes)가 증식하기 좋은 환경이 된다. Increased dihydrotestosterone (DHT), increased sensitivity of DHT receptors or increased androgen by type 1 5α-reductase in the skin increases sebum secretion. In this process, stearoyl-CoA desaturase-1 (SCD-1), a type of unsaturated fatty acid biosynthesis enzyme, binds to the transcriptional regulatory SRE (sterol regulatory element) and contains cholesterol and fatty acids Thereby controlling lipogenesis. If the sebum is not released smoothly from the skin, it will block the air circulation of the pores and become a good environment for the proliferation of anaerobic bacterium, P. acnes .
프로박테리움 아크네는 지질분해효소와 주화성인자(chemotactic factor) 등을 분비하여 유리지방산을 만들고 모공 주위로 다형핵백혈구를 끌어들인다. 그리고 다형핵 백혈구가 프로박테리움 아크네를 포식하면 가수분해효소를 분비하여 모공벽을 파괴하게 되고 모공 내에 머물던 내용물이 진피 내로 유출되어 염증 반응과 이물 반응이 일어나게 된다. 여드름에서 염증 반응을 일으키는 또 다른 요인으로는 세균에 대한 면역기능에 관여하는 톨-유사 수용체(toll-like receptor; TLR)가 프로박테리움 아크네를 비정상 균으로 인지하여 사이토카인 등의 염증 물질을 분비하기 때문이다.ProBacterium acne secretes lipolytic enzymes and chemotactic factors to create free fatty acids and attract polymorphonuclear leukocytes around the pores. When polymorphonuclear leukocytes proliferate, it secretes hydrolytic enzymes and destroys the pore wall. The contents of the pores leak into the dermis, causing inflammation and foreign body reaction. Another factor that causes inflammation in acne is toll-like receptor (TLR), which is involved in immune function to bacteria, recognizes pro-bacterial acnes as abnormal bacteria and secretes inflammatory substances such as cytokines .
이러한 여드름은 피지분비 조절, 각질 관리, 원인균의 제거 및 염증 반응 억제 등의 방법으로 치료 할 수 있다. 항균효과를 갖는 세안제를 사용하는 것이 여드름 치료에 도움을 줄 수 있다. 다만 각질 제거 제품의 과도한 사용은 피부에 자극을 주어 오히려 여드름을 악화시킬 수 있다.These acne can be treated by methods such as controlling sebaceous glands, managing keratin, removing pathogenic bacteria, and inhibiting inflammation. Using antiseptic cleansers can help to treat acne. Excessive use of exfoliants can irritate the skin, which can make acne worse.
최근에는 벤조일과산화물, 항생제와 같은 항균제와 레티노이드가 주된 국소 치료제로 주목 받고 있으나, 벤조일과산화물은 피부 건조와 자극 등의 부작용을 일으킬 수 있으며, 비타민 A 유도체인 레티노이드 역시 건조, 가려움, 작열감, 및 홍반 등을 초래할 수 있으며 있으며 일광 노출 시 화상에 대한 주의가 우려된다.Recently, antibiotics such as benzoyl peroxide and antibiotics and retinoids have been attracting attention as topical treatments. However, benzoyl peroxide may cause side effects such as skin dryness and irritation, and retinoids such as vitamin A derivatives may also cause dryness, itching, burning sensation, And there is concern about burns when exposed to sunlight.
본 발명의 목적은 독성이 낮아 별도의 부작용을 발생시키지 않으면서, 염증 매개 인자의 억제를 통한 피부 항염 작용과 지질 생성 효소의 억제를 통한 피부 피지 분비 억제 효과를 나타내어 여드름성 피부의 증상을 완화시켜 주는 피부 항염, 피부 피지 분비 억제용, 또는 여드름 개선용 조성물을 제공하는 것에 있다.It is an object of the present invention to alleviate the symptoms of acne skin by exhibiting skin anti-inflammatory action through suppression of inflammatory mediators and suppression of lipid-producing enzyme by inhibiting skin sebum secretion without causing any side effects due to low toxicity And to provide a composition for improving skin irritation, suppressing the secretion of skin sebum, or improving acne.
상기 목적을 달성하기 위하여, 본 발명은 일 측면에 있어서 홍화 추출물, 타임 추출물, 및 타마린드 추출물 중 하나 이상을 유효성분으로 포함하는 피부 항염, 피부 피지 분비 억제용, 또는 여드름 개선용 조성물을 제공한다.In order to achieve the above object, the present invention provides, in one aspect, a composition for improving skin irritation, suppressing the secretion of skin sebum, or improving acne, comprising at least one of safflower extract, time extract and tamarind extract as an active ingredient .
또한, 본 발명의 일측면에 있어서, 이러한 피부 항염, 피부 피지 분비 억제용, 또는 여드름 개선용 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용될 수 있다.In addition, in one aspect of the present invention, the composition for treating skin inflammation, inhibiting the secretion of skin sebum, or improving acne can be used in cosmetics, external preparation for skin, or hygiene products.
본 발명의 일측면에 따른 피부 항염 조성물은 천연 식물로부터 유래한 유효성분을 사용하여 종래 염증 치료제에 비하여 부작용의 위험이 적고 안전성이 보장된 상태에서 현저하게 우수한 피부 항염 효과를 나타낸다. The skin anti-inflammatory composition according to one aspect of the present invention exhibits a remarkably superior skin anti-inflammatory effect in a state where the risk of side effects is low and the safety is assured compared with the conventional inflammatory agent using the active ingredient derived from a natural plant.
또한 본 발명의 일측면에 따른 피부 피지 분비 억제용 조성물은 피부 지질 생성과 관련된 인자의 발현을 현저하게 저해하여, 피부에서의 피지 분비를 현저하게 억제하면서 제품 사용시 안정성이 보장되고 가격 경쟁력이 우수한 제품을 제조할 수 있는 효과를 나타낸다.In addition, the composition for suppressing the secretion of skin sebum according to one aspect of the present invention remarkably inhibits the expression of factors related to skin lipid production, thereby remarkably suppressing sebum secretion in the skin, Can be produced.
또한 본 발명의 일측면에 따른 여드름 개선용 조성물은 현저한 피부 항염 효과와 피부 피지 분비 억제 효과를 통하여 여드름성 피부의 증상을 현저하게 완화하는 효과를 나타낸다.In addition, the composition for improving acne according to one aspect of the present invention remarkably alleviates symptoms of acne skin through a remarkable skin anti-inflammatory effect and an effect of inhibiting secretion of skin sebum.
도 1은 본 발명의 일측면에 따른 실시예의 세포 독성을 확인하기 위해 인간 각질형성세포의 세포 생존율에 미치는 영향을 나타낸 그래프이다.
도 2는 자외선B(UVB, Ultraviolet B)에 의해 유도된 염증 반응에서 본 발명의 일측면에 따른 실시예의 NF-κB(nuclear factor kappa-light-chain-enhancer of activated B cells; 세포 핵 전사인자)에 대한 발현 저해 정도를 나타낸 그래프이다.
도 3은 디하이드로테스토스테론에 의해 유도된 불포화 지방산 생합성 효소인 SCD-1에 대한 본 발명의 일측면에 따른 실시예의 발현 저해 정도를 나타낸 그래프이다.FIG. 1 is a graph showing the effect of human keratinocytes on cell survival rate in order to confirm cytotoxicity of an example according to one aspect of the present invention.
FIG. 2 is a graph showing the effect of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) in the inflammatory reaction induced by UVB (Ultraviolet B) Of the present invention.
FIG. 3 is a graph showing the degree of inhibition of expression of SCD-1, an unsaturated fatty acid biosynthesis enzyme induced by dihydrotestosterone, according to an embodiment of the present invention.
본 발명의 일측면에 있어서, "피부"는 생물의 외부를 덮고 있는 기관으로서 기관의 바깥쪽에서부터 표피, 진피 및 피하지방층으로 구성되고 얼굴 또는 몸 전체의 외부를 덮는 조직뿐만 아니라, 두피 및 모발을 포함하는 가장 넓은 개념이다.In one aspect of the present invention, "skin" is an organ covering the outside of an organism. The skin is composed of the epidermis, the dermis, and the subcutaneous fat layer from the outside of the organ and not only the tissue covering the outside of the face or the whole body, It is the broadest concept to include.
본 발명의 일측면에 있어서, "추출물"은 추출을 수행하는 방법, 추출 용매, 추출된 성분 또는 추출물의 형태와 무관하게, 천연물로부터 수득된 물질을 모두 포함하는 것이며 또한 천연물로부터 수득된 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질까지도 모두 포함하는 광범위한 개념이다.In one aspect of the invention, the term "extract" includes all of the substances obtained from natural products, regardless of the method of performing the extraction, the extraction solvent, the extracted components or the form of the extract, And even materials that can be obtained by processing or treating them in other ways.
본 발명의 일 측면에 있어서, "홍화 추출물," "타임 추출물," "타마린드 추출물"은 각 식물을 원료로 추출을 수행하여 수득된 물질을 모두 포함하는 것이며, 예를 들어 추출을 수행하는 과정에서 열, 산, 염기, 효소 등으로 식물을 처리할 수 있고, 이렇게 식물로부터 수득된 물질을 추출 후 다른 방법으로 가공 처리하여 수득되는 물질까지도 모두 포함하는 광범위한 개념이다.In one aspect of the present invention, "safflower extract," " time extract, "" tamarind extract "include all substances obtained by extracting each plant as a raw material. For example, Is a broad concept that includes all of the substances obtained by treating plants with heat, acids, bases, enzymes and the like, and extracting the substances obtained from the plants and processing them by other methods.
본 발명의 일측면에 있어서, "홍화(Carthamus tinctorius)," "타임(Thymus vulgaris)," 및 "타마린드(Tamarindus indica)"는 각 식물 초본 또는 목본의 어린순, 잎, 꽃, 줄기, 껍질, 열매, 종자, 뿌리 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상일 수 있다.In one aspect of the present invention, " Carthamus tinctorius ,"" Thymus vulgaris ," and " Tamarindus indica " refer to the leaves, flowers, stems, Fruit, seed, root, and combinations thereof.
이하에서는 본 발명에 대하여 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 일측면에 있어서, 홍화 추출물, 타임 추출물, 및 타마린드 추출물 중 하나 이상을 유효성분으로 포함하는 피부 항염 조성물에 관한 것일 수 있다.In one aspect, the present invention may relate to a skin anti-inflammatory composition comprising, as an active ingredient, at least one of safflower extract, time extract, and tamarind extract.
본 발명은 일측면에 있어서, 홍화 추출물, 타임 추출물, 및 타마린드 추출물 중 하나 이상을 유효성분으로 포함하는 피부 피지 분비 억제용 조성물에 관한 것일 수 있다.In one aspect, the present invention may relate to a composition for inhibiting secretion of skin sebum comprising at least one of safflower extract, time extract, and tamarind extract as an active ingredient.
본 발명은 일측면에 있어서, 홍화 추출물, 타임 추출물, 및 타마린드 추출물 중 하나 이상을 유효성분으로 포함하는 피부 여드름 개선용 조성물에 관한 것일 수 있다.In one aspect, the present invention relates to a composition for improving skin acne comprising at least one of safflower extract, time extract, and tamarind extract as an active ingredient.
홍화(Carthamus tinctorius)는 아시아, 이집트, 남유럽, 북아메리카, 오스트레일리아 등지에서 재배되는 한해살이풀로, 잇꽃이라고도 부른다. 아침 이슬에 젖었을 때 꽃을 따서 말린 것을 홍화라 하여 한방에서는 부인병, 통경, 복통에 쓰였다고 하고, 과거에는 혼인에 쓰는 붉은색 연지의 재료로 사용하였다고 한다.Safflower ( Carthamus tinctorius ) is an annual plant grown in Asia, Egypt, Southern Europe, North America and Australia. It is also called safflower. In the morning when the dew was wet, the dried flower was used as a safflower, and in one room it was used for women's disease, bronchitis and abdominal pain.
본 발명의 일측면에 있어서, 홍화 추출물은 홍화 초본의 종자 추출물 일 수 있다.In one aspect of the present invention, the safflower extract may be a seed extract of safflower herb.
타임(Thymus vulgaris)은 지중해 연안이 원산지인 여러해살이풀로, 선백리향이라고도 불리며 우리 나라의 백리향과 비슷하지만 곧게 서는 점에서 다르며 잎에 털이 있다. 타임은 다른 허브와 구별되는 강한 향을 가지고 있으며, 이 향기는 장기간 저장해도 손실되지 않는다. 타임의 건조한 꽃은 천연 방충 및 방향제 역할을 하기도 한다. 힘과 에너지를 얻게 해준다는 설이 있어서 최음제로도 이용되었다. Thymus vulgaris ( Thymus vulgaris ) is a perennial herb that originated in the Mediterranean coast. It is also called Thyme Thyme. Thymus vulgaris is similar to Thyme in our country, but it is different in its straight point and hairy on the leaves. Time has a strong smell that distinguishes it from other herbs, and this smell is not lost even after long-term storage. Time dried flowers are also natural insecticides and fragrances. It was also used as an aphrodisiac because it was said that it would gain power and energy.
본 발명의 일측면에 있어서, 타임 추출물은 타임 초본의 잎, 줄기 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물일 수 있다.In one aspect of the invention, the time extract may be one or more extracts selected from the group consisting of time-herbal leaves, stems, and combinations thereof.
타마린드(Tamarindus indica)는 인도네시아·인도 등의 건조한 열대지방에 분포하는 콩과의 상록 고목이다. 수형이 아름답기 때문에 가로수나 공원수로 심으며, 심재는 검붉은색이므로 재목으로 많이 쓴다. 열매는 날로 먹거나 조미료와 약재로 쓴다. 인도에서는 어린이들의 완하제, 괴혈병 치료, 카레의 조미료, 청량음료의 재료 등으로 쓴다. Tamarindus indica is an evergreen tree with beans distributed in arid tropics such as Indonesia and India. It is planted with trees and trees because it is beautiful, and its core material is dark red, so it is often used as timber. Fruits are eaten raw or seasoned and medicinal. In India, children are treated with laxatives, scurvy treatment, curry seasonings, and soft drinks.
본 발명의 일측면에 있어서, 타마린드 추출물은 타마린드 목본의 종자 추출물일 수 있다.In one aspect of the invention, the tamarind extract may be a seed extract of tamarind tree.
본 발명의 일측면에 있어서, 조성물 총 부피에 대하여 추출물의 총 함량은 0.0001 부피% 이상 5 부피% 미만, 0.001 내지 4 부피%, 0.05 내지 3 부피%, 0.1 내지 2 부피%, 0.5 내지 1.5 부피%, 0.8 내지 1.2 부피% 일 수 있다. 또한, 조성물 총 부피에 대하여 추출물의 총 함량은 예를 들어 1.0 부피% 일 수 있다. 추출물의 총 함량이 지나치게 소량이면 본 발명의 목적을 달성하기 위한 피부 항염, 피부 피비 분비 억제 효과, 또는 피부 여드름 개선 효과를 나타낼 수 없고, 5 부피% 이상이면 각질형성세포에 대하여 독성을 나타내어 안전성에 문제를 일으킬 수 있다.In one aspect of the invention, the total content of the extract relative to the total volume of the composition is from 0.0001% by volume to less than 5% by volume, from 0.001 to 4% by volume, from 0.05 to 3% by volume, from 0.1 to 2% , And 0.8 to 1.2% by volume. In addition, the total content of the extract relative to the total volume of the composition may be, for example, 1.0% by volume. If the total amount of the extracts is too small, it can not exhibit skin anti-inflammatory effect, skin pebbles inhibitory effect, or skin acne improvement effect for achieving the object of the present invention. If it is 5 vol% or more, it exhibits toxicity to keratinocytes, It can cause problems.
본 발명의 일측면에 있어서, 추출물은 물; 유기용매; 및 이들의 혼합물로 이루어진 군에서 선택된 하나 이상으로 추출한 것일 수 있다.In one aspect of the invention, the extract is selected from the group consisting of water; Organic solvent; And a mixture thereof.
본 발명의 일측면에 있어서, 물은 증류수 또는 정제수를 포함하며, 유기 용매는 C1~C6의 저급 알코올, 아세톤, 에테르, 프로판디올, 에틸아세테이트, 디에틸에테르, 에틸메틸케톤, 클로로포름, 헥산, 메틸렌 클로라이드, 에틸 아세테이트, 부틸렌글리콜, 헥산디올, 디프로필렌글리콜 및 프로필렌글리콜로 이루어진 군에서 선택된 하나 이상을 포함하나, 이에 제한되는 것은 아니다.In one aspect of the present invention, water comprises distilled water or purified water, and the organic solvent is selected from the group consisting of C1 to C6 lower alcohols, acetone, ether, propanediol, ethyl acetate, diethyl ether, ethyl methyl ketone, chloroform, But are not limited to, one or more selected from the group consisting of chloride, ethyl acetate, butylene glycol, hexanediol, dipropylene glycol, and propylene glycol.
본 발명의 일측면에 있어서, 상기 추출물은 정제수, 디프로필렌글리콜 및 1,2-헥산디올의 혼합용매로 추출된 것일 수 있다. 예를 들어, 상기 혼합용매는 그 총 질량을 기준으로 70 내지 85 질량%의 정제수, 15 내지 25 질량%의 디프로필렌글리콜 및 1 내지 5 질량%의 1,2-헥산디올을 포함하는 것일 수 있다. 또한, 상기 혼합용매에 포함된 정제수의 함량은 혼합용매의 총 질량에 대하여 70 내지 85 질량%, 73 내지 83 질량%, 또는 75 내지 80 질량%일 수 있으며; 디프로필렌글리콜의 함량은 혼합용매의 총 질량에 대하여 10 내지 30 질량%, 15 내지 25 질량%, 또는 18 내지 22 질량%일 수 있으며; 1,2-헥산디올의 함량은 혼합용매의 총 질량에 대해 0.1 내지 7 질량%, 1 내지 5 질량%, 또는 2 내지 4 질량%일 수 있으나, 이에 제한되지는 않는다.In one aspect of the present invention, the extract may be one extracted with a mixed solvent of purified water, dipropylene glycol and 1,2-hexanediol. For example, the mixed solvent may include 70 to 85 mass% of purified water, 15 to 25 mass% of dipropylene glycol and 1 to 5 mass% of 1,2-hexanediol based on the total mass . Also, the content of the purified water contained in the mixed solvent may be 70 to 85 mass%, 73 to 83 mass%, or 75 to 80 mass% based on the total mass of the mixed solvent; The content of dipropylene glycol may be 10 to 30 mass%, 15 to 25 mass%, or 18 to 22 mass%, based on the total mass of the mixed solvent; The content of 1,2-hexanediol may be 0.1 to 7 mass%, 1 to 5 mass%, or 2 to 4 mass%, based on the total mass of the mixed solvent, but is not limited thereto.
본 발명의 일 측면에 있어서, 상기 추출물은 예를 들어, 열수 추출, 가열 추출, 냉침 추출, 환류 추출, 환류 냉각 추출, 또는 초음파 추출 등을 이용하여 추출될 수 있고 통상의 기술자에게 자명한 추출 공정이라면 제한되지 않는다. 추출물의 추출은 실온에서 수행될 수 있으나 효율적인 추출을 위해 약 40 내지 120℃, 80 내지 110℃, 또는 85 내지 95℃의 조건에서 추출 할 수 있으며, 구체적으로 약 90℃의 온도와 같은 가온 조건에서 추출할 수 있으나, 이에 제한되는 것은 아니다. 추출시간은 약 1 내지 4시간, 구체적으로는 약 1.5 내지 2.5 시간 동안 수행할 수 있으나 이에 제한되는 것은 아니며, 이는 추출 용매 및 추출 온도 등의 조건에 따라 달라질 수 있다. 예를 들어, 추출 용매가 물인 경우에는 90~100℃, 에탄올인 경우에는 65~70℃에서 수행될 수 있다. 추출은 유효성분의 추출 수득량을 높이기 위해 1 회 이상 여러 번 추출할 수 있으며, 예를 들어 1 내지 5회로 연속 추출하여 합한 추출액을 이용할 수 있다.In one aspect of the present invention, the extract can be extracted using, for example, hot water extraction, heat extraction, cold extraction, reflux extraction, reflux cooling extraction, ultrasonic extraction, or the like, . Extraction can be carried out at room temperature, but extraction can be carried out at about 40 to 120 DEG C, 80 to 110 DEG C, or 85 to 95 DEG C for efficient extraction, specifically at a temperature of about 90 DEG C But is not limited thereto. The extraction time may be about 1 to 4 hours, specifically about 1.5 to 2.5 hours. However, the extraction time may vary depending on conditions such as extraction solvent and extraction temperature. For example, the extraction solvent may be performed at 90 to 100 ° C in the case of water and at 65 to 70 ° C in the case of ethanol. The extraction can be carried out one or more times several times in order to increase the extraction yield of the active ingredient, and for example, one to five consecutive extracts can be used.
피부의 여드름에서 염증 반응을 일으키는 요인으로는 세균에 대한 면역기능에 관여하는 톨-유사 수용체(toll-like receptor; TLR)가 프로박테리움 아크네를 비정상 균으로 인지하여 NF-κB와 같은 사이토카인 등의 염증 물질을 분비하기 때문이다.The cause of inflammation in acne of skin is toll-like receptor (TLR), which is involved in immune function to bacteria, is known to be an abnormal microorganism of pro-bacterium acne, and cytokines such as NF-κB Of the inflammatory substance secrete.
본 발명의 일측면에 따른 조성물은 염증 반응에 관여하는 사이토카인인 NF-κB의 발현을 저해하여 피부 항염 활성 효과를 나타낸다.The composition according to one aspect of the present invention inhibits the expression of NF-κB, which is a cytokine involved in an inflammatory reaction, and exhibits an anti-inflammatory activity.
본 발명의 일측면에 따른 조성물은 스테아로일-코엔자임A 불포화효소-1(stearoyl-CoA desaturase 1; SCD-1)의 발현을 저해하여 불포화 지방산이 합성되는 것을 억제하고 피부의 피지 분비를 억제하는 작용을 나타낸다.The composition according to one aspect of the present invention inhibits the expression of stearoyl-CoA desaturase 1 (SCD-1) to inhibit the synthesis of unsaturated fatty acids and suppresses sebaceous secretion of the skin Lt; / RTI >
본 발명의 일측면에 따른 조성물은 위 피부 항염 활성 및 피부 피지 분비 억제 활성을 통하여 피부 여드름 개선 효과를 나타낸다. The composition according to one aspect of the present invention exhibits skin acne improvement effect through gastric anti-inflammatory activity and skin anti-secretion activity.
본 발명의 일측면에 있어서, 상기 조성물은 홍화 추출물, 타임 추출물 및 타마린드 추출물 중의 2 이상의 조합을 유효성분으로 포함할 수 있다. 본 발명의 일측면에 따른 조성물은 홍화 추출물, 타임 추출물 및 타마린드 추출물 중의 2 이상의 조합에 의하여 이들 각각을 포함하는 경우에 비해 현저하게 우수한 피부 항염 효과 및 피부 보습 효과를 나타낸다.In one aspect of the present invention, the composition may contain, as an active ingredient, a combination of two or more of safflower extract, time extract and tamarind extract. The composition according to one aspect of the present invention exhibits remarkably superior skin anti-inflammatory effect and skin moisturizing effect compared with the case of containing each of them by combination of two or more of safflower extract, time extract and tamarind extract.
본 발명의 일측면에 있어서, 상기 조성물에서 홍화 추출물:타임 추출물:타마린드 추출물의 부피비는 1~9:1~9:1~9 의 정수 비일 수 있다. 구체적으로, 상기 조성물에서 홍화 추출물:타임 추출물:타마린드 추출물의 부피비는 1~5:1~5:1~5, 1~3:1~3:1~3, 1~2.7:1~2.7:1~2.7, 1~2.3:1~2.3:1~2.3, 또는 1~2:1~2:1~2일 수 있다. 또한, 상기 조성물에서 홍화 추출물:타임 추출물:타마린드 추출물의 부피비는 예를 들어 약 1:2:2일 수 있다.In one aspect of the present invention, the volume ratio of safflower extract: time extract: tamarind extract in the composition may be an integer ratio of 1 to 9: 1 to 9: 1 to 9. Specifically, the volume ratio of safflower extract: time extract: tamarind extract in the composition is 1: 5: 1 to 5: 1 to 5: 1: 3: 1 to 3: 1 to 2.7: 1 to 2.3: 1 to 2.3: 1 to 2.3, or 1: 2: 1 to 2: 1 to 2. In addition, the volume ratio of safflower extract: time extract: tamarind extract in the composition may be, for example, about 1: 2: 2.
본 발명의 일측면에 있어서, 상기 조성물은 본 발명의 효과를 저해하지 않는 범위 내에서 통상의 기술자가 자명하게 적용할 수 있는 통상적이고 공지된 성분으로 항산화제, 보존제, 흡수제, 각질제거제, 증점제, 선크림제제, 유화제, 계면활성제, 향료, 소취제, 안정화제, 피부 보호제, 및 pH 조절제 중 하나 이상을 더 포함할 수 있다.In one aspect of the present invention, the composition may contain conventional and well-known ingredients that can be readily applied by a person skilled in the art to the extent that the effects of the present invention are not impaired, such as antioxidants, preservatives, absorbents, exfoliants, Sunscreen preparations, emulsifiers, surfactants, perfumes, deodorants, stabilizers, skin protectants, and pH adjusting agents.
본 발명의 일측면에 있어서, 항산화제는 본 발명의 효과를 저해하지 않는 범위 내에서 토코페릴아세테이트, 토코페롤, 디부틸히드록시톨루엔(BHT), 아세틸 시스테인, 아스코르브산 폴리펩타이드, 에리소르빈산, 디아밀하이드로퀴논 및 아스코르빌 팔미테이트로 구성된 군으로부터 선택된 하나 이상 일 수 있다. 항산화제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the antioxidant may be selected from the group consisting of tocopheryl acetate, tocopherol, dibutylhydroxytoluene (BHT), acetylcysteine, ascorbic acid polypeptide, erythorbic acid, Hydroquinone, and ascorbyl palmitate. The antioxidant may be included in a conventionally used amount, for example, from 0.01 to 2% by weight based on the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 보존제는 본 발명의 효과를 저해하지 않는 범위 내에서 메틸파라벤, 프로필파라벤, 페녹시에탄올, 포타슘소르베이트, 데하이드로 아세트산(Dehydroacetic Acid), 펜탄디올 및 소르브산으로 구성된 군으로부터 선택된 하나 이상 일 수 있다. 보존제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the preservative may be selected from the group consisting of methylparaben, propylparaben, phenoxyethanol, potassium sorbate, Dehydroacetic Acid, pentanediol, and sorbic acid to the extent that the effect of the present invention is not impaired. Lt; / RTI > Preservatives are conventionally used as, for example, but not limited to, 0.01 to 2% by weight based on the total weight of the composition.
본 발명의 일측면에 있어서, 흡수제는 알루미늄 전분 옥테닐숙신에이트, 카올린, 옥수수 전분, 오트 전분, 시클로덱스트린, 탈크, 및 제올라이트로 구성된 군으로부터 선택된 하나 이상일 수 있다. 흡수제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the invention, the absorbent may be at least one selected from the group consisting of aluminum starch octenyl succinate, kaolin, corn starch, oat starch, cyclodextrin, talc, and zeolite. The absorbent is conventionally used as, for example, but not limited to, 0.01 to 2% by weight based on the total weight of the composition.
본 발명의 일측면에 있어서, 각질제거제는 알파-히드록시산, 베타-히드록시산, 락트산, 글리콜산, 살리실산 및 이의 염으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 각질제거제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the exfoliant may be at least one selected from the group consisting of alpha-hydroxy acid, beta-hydroxy acid, lactic acid, glycolic acid, salicylic acid and salts thereof. The exfoliant is a conventionally used amount, for example, but not limited to, 0.01 to 2% by weight based on the total weight of the composition.
본 발명의 일측면에 있어서, 증점제는 카르복실산 폴리머(예를 들어, 아크릴산), 파라핀, 가교된 폴리아크릴레이트 폴리머, 폴리아크릴아미드 폴리머(예를 들어, 폴리아크릴아미드, 또는 이소파라핀), 폴리사카라이드(예를 들어 셀룰로오스), 및 검(예를 들어, 한천, 알긴, 알긴산암모늄, 또는 젤라틴)으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 증점제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the invention, the thickening agent is selected from the group consisting of carboxylic acid polymers (e.g., acrylic acid), paraffin, crosslinked polyacrylate polymers, polyacrylamide polymers (e.g., polyacrylamide or isoparaffin) Saccharide (for example, cellulose), and gum (for example, agar, algin, ammonium alginate, or gelatin). Thickening agents can be included, for example, in amounts of from 0.01 to 2% by weight, based on the total weight of the composition, but are not limited thereto.
본 발명의 일측면에 있어서, 선크림제제는 파라-아미노벤조산(PABA), 글리세릴 PABA, 옥틸디메틸 PABA, 부틸 PABA, 신나메이트, 안트라닐레이트, 살리실레이트, 카올린, 탈크, 페트롤라툼, 및 메탈 옥사이드로 구성된 군으로부터 선택된 하나 이상일 수 있다. 선크림제제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the sunscreen preparation comprises at least one compound selected from the group consisting of para-aminobenzoic acid (PABA), glyceryl PABA, octyldimethyl PABA, butyl PABA, cinnamate, anthranilate, salicylate, kaolin, talc, petrolatum, Oxide. ≪ / RTI > The sunscreen preparation may be included in a conventionally used amount, for example, from 0.01 to 2% by weight based on the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 유화제는 본 발명의 효과를 저해하지 않는 범위 내에서 밀납, 세테아릴 글루코사이드, 카르복시비닐폴리머, 폴리솔베이트 20, 폴리솔베이트 60, 도데실벤젠술폰산염, 소르비탄 지방산 에스테르, 모노스테아르산 글리세린, 스테아르산, 팔미트산, 스테아릴 알코올, 베헤닐 알코올, 및 레시틴으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 이러한 유화제는 조성물의 총 중량에 대해 0.01 내지 4 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the present invention, the emulsifying agent may contain, within the range not impairing the effect of the present invention, wax, cetearyl glucoside, carboxyvinyl polymer,
본 발명의 일측면에 있어서, 계면활성제는 본 발명의 효과를 저해하지 않는 범위 내에서 소르비탄세스퀴올레이트, 디소듐코코암포디아세테이트, 소듐코코암포아세테이트, 피이지-12 노닐페닐에테르, 피이지-120메틸글루코오스디올리에이트, 및 포타슘코코일글리시네이트로 구성된 군으로부터 선택된 하나 이상일 수 있다. 계면활성제는 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이에 제한되는 것은 아니다.In one aspect of the present invention, the surfactant may contain, in a range not inhibiting the effect of the present invention, sorbitan sesquioleate, disodium cocoamphodiacetate, sodium cocoamphoacetate, phage-12 nonylphenyl ether, -120 methyl glucose diolate, and potassium cocoyl glycinate. The surfactant may be included in the composition in an amount of 0.01 to 2% by weight based on the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 향료는 허브, 일랑일랑 정유, 오렌지 정유, 카난가 정유, 계피정유, 케모마일 꽃추출물, 레몬 글래스 정유, 레몬 정유, 및 로즈마리 정유로 구성된 군으로부터 선택된 하나 이상일 수 있다. 향료는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the perfume can be at least one selected from the group consisting of herb, ylang ylang essential oil, orange essential oil, cananga essential oil, cinnamon essential oil, kemomilla flower extract, lemon glass essential oil, lemon essential oil, and rosemary essential oil. Fragrances are typically used as, for example, 0.01 to 2% by weight, based on the total weight of the composition, but are not limited thereto.
본 발명의 일측면에 있어서, 소취제는 과망간산 칼륨, 표백분, 편백나무추출물, 대나무 추출물, 녹차 추출물, 솔잎 추출물, 및 레몬즙으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 소취제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다. In one aspect of the present invention, the deodorant may be at least one selected from the group consisting of potassium permanganate, bleaching powder, bamboo extract, bamboo extract, green tea extract, pine leaf extract, and lemon juice. The deodorant may be conventionally used as, for example, but not limited to, 0.01 to 2% by weight based on the total weight of the composition.
본 발명의 일측면에 있어서, 안정화제는 아황산나트륨, 아스코르빈산, 카로티노이드, 레티놀, 티오글리세롤, 및 시스테인으로 구성된 군으로부터 선택된 하나 이상일 수 있다. 안정화제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다. In one aspect of the invention, the stabilizer may be at least one selected from the group consisting of sodium sulfite, ascorbic acid, carotenoid, retinol, thioglycerol, and cysteine. Stabilizers can be included in a conventionally used amount, for example, from 0.01 to 2% by weight based on the total weight of the composition, but are not limited thereto.
본 발명의 일측면에 있어서, 피부 보호제는 카프릴릭/카프릭 트리글리세라이드, 세테아릴 알코올, 스쿠알란, 알란토인, 베타글루칸, 히알루론산 추출물, 로즈마리 추출물, 토코페릴 아세테이트, 콜로스트럼, 알란토인, 및 D-판테놀로 구성된 군으로부터 선택된 하나 이상일 수 있다. 피부 보호제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다. In one aspect of the invention, the skin protection agent is selected from the group consisting of caprylic / capric triglyceride, cetearyl alcohol, squalane, allantoin, betaglucan, hyaluronic acid extract, rosemary extract, tocopheryl acetate, colostrum, D-panthenol. ≪ / RTI > The skin protectant is conventionally used as, for example, but not limited to, 0.01 to 2% by weight based on the total weight of the composition.
본 발명의 일측면에 있어서, pH 조절제는 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨. 트리에탄올아민 및 탄산 칼슘으로 구성된 군으로부터 선택된 하나 이상일 수 있다. pH 조절제는 통상적으로 사용되는 함량으로서 예를 들어 조성물의 총 중량에 대해 0.01 내지 2 중량%로 포함될 수 있으나 이제 제한되는 것은 아니다.In one aspect of the present invention, the pH adjusting agent is selected from the group consisting of citric acid, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumarate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate. Triethanolamine, and calcium carbonate. The pH adjusting agent is conventionally used as, for example, 0.01 to 2% by weight based on the total weight of the composition, but is not limited thereto.
본 발명의 일측면에 있어서, 상기 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용될 수 있다.In one aspect of the present invention, the composition can be used in cosmetics, external preparation for skin, or sanitary products.
본 발명의 일측면에 있어서, 화장품은 화장수, 에센스, 선크림, 선로션, 크림류 등과 같은 기초 화장품; 가루분, 고형백분, 크림백분, 파운데이션, 입술연지, 눈썹연필, 미조료 등과 같은 메이크업 화장품; 헤어 로션, 헤어 토닉, 액상 및 유상 정발료, 헤어 크림, 헤어 트리트먼트 크림, 샴푸, 헤어 스프레이 등과 같은 헤어케어 화장품; 팩과 같은 얼굴 케어 화장품; 또는 비누, 클렌징폼, 클렌징로션, 클렌징크림, 바디로션 및 바디클린저 등과 같은 바디케어 화장품일 수 있다.In one aspect of the present invention, the cosmetics may be cosmetics such as lotion, essence, sun cream, sun lotion, cream, etc .; Make-up cosmetics such as powder, solid white powder, cream white powder, foundation, lip balm, eyebrow pencil, and fine powder; Hair care cosmetics such as hair lotions, hair tonics, liquid and oil care products, hair creams, hair treatment creams, shampoos, hair sprays and the like; Face care cosmetics such as packs; Or body care cosmetics such as soaps, cleansing foams, cleansing lotions, cleansing creams, body lotions and body cleansers.
본 발명의 일측면에 있어서, 피부 외용제는 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 및 겔제로 구성된 군으로부터 선택된 어느 하나 일 수 있다. In one aspect of the present invention, the external preparation for skin may be any one selected from the group consisting of ointments, lotions, sprays, patches, creams, powders, suspensions, and gels.
본 발명의 일측면에 있어서, 위생용품은 물티슈, 티슈, 기저귀, 생리대, 위생 와이프, 습윤 와이프, 클리닝 와이프, 훼이셜 와이프, 스킨케어 와이프, 및 지한제 와이프로 구성된 군으로부터 선택된 어느 하나일 수 있다.In one aspect of the present invention, the sanitary article can be any one selected from the group consisting of a wipe, a tissue, a diaper, a sanitary napkin, a sanitary wipe, a wet wipe, a cleaning wipe, a facial wipe, a skin care wipe, and a wiping wipe.
이하, 실시예 및 시험예를 들어 본 명세서의 구성 및 효과를 보다 구체적으로 설명한다. 그러나 이들 실시예 및 시험예는 본 명세서에 대한 이해를 돕기 위해 예시의 목적으로만 제공된 것일 뿐 본 명세서의 범주 및 범위가 하기 예에 의해 제한되는 것은 아니다.Hereinafter, the configurations and effects of the present invention will be described in more detail with reference to examples and test examples. However, these examples and test examples are provided for illustrative purposes only in order to facilitate understanding of the present specification, and the scope and range of the present specification are not limited by the following examples.
[실시예 1~4, 대조예 및 비교예][Examples 1 to 4, Controls and Comparative Examples]
(1) 홍화 초본의 종자를 1:20의 중량비로 추출 용매(정제수 77 질량%, 디프로필렌 글리콜 20 질량%, 및 1,2-헥산디올 3 질량%로 구성됨)에 넣어 90℃에서 2시간 동안 추출후 잔류용매를 제거하여 홍화 추출물을 제조하였다.(1) Safflower seeds were seeded in an extraction solvent (consisting of 77 mass% of purified water, 20 mass% of dipropylene glycol, and 3 mass% of 1,2-hexanediol) at a weight ratio of 1:20, After the extraction, the residual solvent was removed to prepare a safflower extract.
(2) 상기 홍화 대신 타임 초본의 잎 및 줄기로 구성된 혼합물을 동일한 방법에 의해 추출하여 타임 추출물을 제조하였으며, 타마린드 목본의 종자를 동일한 방법에 의해 추출하여 타마린드 추출물을 제조하였다.(2) A mixture of timber herb leaves and stems instead of the safflower was extracted by the same method to prepare a time extract. Tamarind extract was prepared by extracting the seeds of tamarind wood by the same method.
(3) 이렇게 제조된 각 추출물을 정제수를 이용하여 10 부피%로 희석한 후, 하기 표 1의 함량으로 하기 배지로 재차 희석하여 실시예 1 내지 4의 조성물을 제조하였다.(3) Each of the extracts thus prepared was diluted to 10 volume% using purified water, and then diluted again with the following media in the contents shown in the following Table 1 to prepare the compositions of Examples 1 to 4.
배지: 소태아 혈청(Fetal Bovine Serum), 100 IU/ml의 페니실린 및 100μg/ml의 스트렙토마이신이 첨가된 DMEM 미디엄(Medium)Medium: DMEM medium supplemented with fetal bovine serum, 100 IU / ml penicillin and 100 μg / ml streptomycin.
(4) 대조예의 경우 아무런 평가 시료(유효 성분)를 첨가하지 않은 것을 의미한다.(4) In the case of the control sample, no evaluation sample (active ingredient) was added.
[시험예 1] 세포 독성 평가[Test Example 1] Cytotoxicity evaluation
(1) 식물 추출물의 세포 독성은 살아있는 세포의 미토콘드리아 활성을 측정하여 세포 생존율을 통해 확인할 수 있는 MTT ASSAY(Sigma, 제품 번호 M5655-100mg)로 측정하였다.(1) The cytotoxicity of the plant extract was measured by MTT ASSAY (Sigma, product number M5655-100 mg), which can be confirmed through cell viability by measuring the mitochondrial activity of living cells.
(2) 먼저 인간 각질형성세포인 HaCaT(GIBCO, 제품번호 HEKa(C-005-5C))을 96-웰 플레이트에 5×105 cell/well의 농도로 각각 분주한 후, 각 웰에 10부피%의 소태아혈청(GIBCO, 제품 번호 12483-020), 100 IU/ml의 페니실린(SIGMA, 제품 번호 M5655) 및 100μg/ml의 스트렙토마이신(SIGMA, 제품 번호 S9137)이 첨가된 DEME 배지(Wellgene, 제품번호 LM001-51)를 넣고 37℃, 5%의 CO2 하에서(이하 세포 배양시 동일한 조건) 18시간 동안 배양하였다. 그 후 배지를 제거하고 PBS로 세척한 뒤, 실시예 1-1 내지 실시예 4와 새로운 DEME 배지를 넣고 18 시간 동안 배양하였다. 18 시간 배양 후, 세포의 생존율 아래 수학식 1을 MTT ASSAY로 측정 및 확인하여 그 결과를 도 1에 나타내었다.(2) First, HaCaT (GIBCO, product number: HEKa (C-005-5C)), which is a human keratinocyte, was dispensed into a 96-well plate at a concentration of 5 × 10 5 cells / well, (Wellgen, St. Louis, MO) supplemented with 100% fetal bovine serum (GIBCO, Cat. No. 12483-020), 100 IU / ml penicillin (SIGMA, Cat. No. M5655) and 100 ug / ml streptomycin (SIGMA, Cat. No. S9137) Product number LM001-51) was added and incubated for 18 hours at 37 ° C under 5% CO 2 (the same conditions for cell culture). Thereafter, the medium was removed, washed with PBS, and fresh DEME medium was added to Examples 1-1 to 4, followed by incubation for 18 hours. After incubation for 18 hours, the cell viability was measured and confirmed by the following formula (1) using MTT ASSAY. The results are shown in FIG.
[수학식 1][Equation 1]
세포 생존율 = (시료첨가구의 흡광도 / 대조구의 흡광도) X 100Cell survival rate = (absorbance of sample added / absorbance of control)
도 1의 결과에 따르면, 홍화 추출물, 타임 추출물, 및 타마린드 추출물의 사용 농도가 5 부피%인 실시예 1-3, 실시예 2-3, 및 실시예 3-3의 경우 세포 생존율이 크게 감소하였다. 이에 5 부피%에 비하여 높은 세포 생존율을 나타내는 1 부피%의 농도를 사용하여 아래 시험예 2, 및 시험예 3의 시험을 수행하였다. 홍화 추출물, 타임 추출물, 및 타마린드 추출물을 조합하여 1 부피%가 되도록 한 실시예 4의 경우, 개별 추출물의 농도가 0.5 부피%보다 낮으므로, 이와 같이 조합한 경우 매우 높은 세포 생존율을 나타내어 독성이 매우 낮은 것을 확인할 수 있다.According to the results shown in Fig. 1, in Examples 1-3, 2-3, and 3-3 in which the concentration of the safflower extract, time extract, and tamarind extract was 5 vol%, the cell survival rate was greatly reduced Respectively. Thus, the tests of Test Example 2 and Test Example 3 were carried out using 1 vol.% Concentration, which shows a higher cell survival rate than 5 vol.%. In case of Example 4 in which 1 volume% is combined with safflower extract, time extract and tamarind extract, the concentration of the individual extract is lower than 0.5 volume%. Therefore, when such a combination is used, the cell survival rate is very high and toxicity Which is very low.
[시험예 2] 식물 추출물의 피부 항염 효과 평가[Test Example 2] Evaluation of skin anti-inflammatory effect of plant extracts
(1) 인간 각질형성세포인 HaCaT(GIBCO, 제품번호 HEKa(C-005-5C))세포를 6-웰 플레이트에 5×105 cell/well의 농도로 각각 분주한 후, 각 웰에 10부피%의 소태아혈청(GIBCO, 제품 번호 12483-020), 100 IU/ml의 페니실린(SIGMA, 제품 번호 M5655) 및 100μg/ml의 스트렙토마이신(SIGMA, 제품 번호 S9137)이 첨가된 DEME 배지(Wellgene, 제품번호 LM001-51)를 넣고 37℃, 5%의 CO2 하에서(이하 세포 배양시 동일한 조건) 2 일간 배양하였다. 배양된 HaCaT 세포를 PBS로 세척하고 실시예 1-2, 실시예 2-2, 실시예 3-2, 실시예 4 및 대조예를 각 웰에 처리하고 동일한 DEME 배지를 이용하여 37℃, 5%의 CO2 하에서 3 일간 배양하였다.(1) Human keratinocytes HaCaT in (GIBCO, product number HEKa (C-005-5C)) cells in a 6-well plate, each dispensed at a concentration of 5 × 10 5 cell / well and then, 10 volume to each well (Wellgen, St. Louis, MO) supplemented with 100% fetal bovine serum (GIBCO, Cat. No. 12483-020), 100 IU / ml penicillin (SIGMA, Cat. No. M5655) and 100 ug / ml streptomycin (SIGMA, Cat. No. S9137) Product number LM001-51) was added and incubated for 2 days at 37 ° C under 5% CO 2 (the same conditions for cell culture). The cultured HaCaT cells were washed with PBS and treated with each of the wells in Examples 1-2, 2-2, 3-2, and 4 and the control, and cultured in the same DEME medium at 37 ° C and 5% Of CO 2 for 3 days.
(2) 배양된 세포에 각각 UVB 를 하기와 같이 처리하여 세포손상을 유도하였다.(2) UVB was applied to the cultured cells as follows to induce cell damage.
- UVB 처리에 의한 세포손상- Cell damage by UVB treatment
상기 (1)에서 배양된 세포의 배지를 제거하고 PBS로 세포를 세척하고 UBP 크로스링커스(UVP Crosslinkers)(UVP, United Kingdom)에서 100 mJ/cm2의 UVB를 10분 동안 조사하여 세포 손상을 유도한 뒤 배지를 교체하여 1 일간 배양하였다.Cells grown in (1) were removed and the cells were washed with PBS. UVB crosslinkers (UVP, United Kingdom) were irradiated with 100 mJ / cm 2 of UVB for 10 minutes to induce cell damage And the medium was replaced and cultured for 1 day.
(3) 이렇게 배양된 세포로부터 항염 관련 유전자의 분석을 위하여 하기와 같은 방법으로 RNA를 추출 및 정량한 다음 cDNA를 합성하여 RT-PCR(Reverse transcription -polymerase chain reaction)을 실시하였다.(3) For the analysis of the anti-inflammation-related gene from the thus cultured cells, RNA was extracted and quantified as follows, and cDNA was synthesized and subjected to reverse transcription-polymerase chain reaction (RT-PCR).
① 상기 (2)에서 시료와 함께 배양 된 세포의 배지를 제거하고 1X PBS로 세포를 세척하였다.In (2), the medium of the cells incubated with the sample was removed, and the cells were washed with 1X PBS.
② 1X PBS를 제거하고 플레이트에 배양 된 세포의 각 웰에 트리아졸 시약 (Invitrogen, USA) 를 세포에 고루 닿도록 넣고 실온에서 3~5분간 방치하였다.② After removing 1X PBS, triazole (Invitrogen, USA) was added to each well of the cells cultured on the plate, and allowed to stand at room temperature for 3 to 5 minutes.
③ 각 웰 안의 세포를 스크래퍼로 조심스럽게 긁어서 마이크로튜브에 모은 뒤 40 μL의 클로로포름을 가하고 섞어주었다.③ Cells in each well were scraped with a scraper, collected in a microtube, and mixed with 40 μL of chloroform.
④ 실온에서 2~3분간 방치 후 12,000rpm, 4℃에서 15분간 원심 분리하였다.④ After standing at room temperature for 2 to 3 minutes, centrifugation was carried out at 12,000 rpm and 4 ° C for 15 minutes.
⑤ 원심 분리 후 투명한 상등액을 새 튜브에 옮긴 후 100 uL의 이소프로필 알코올을 넣고 조심스럽게 뒤집어(invert) 상온에서 10 분간 방치 후 12,000rpm, 4℃에서 10분간 원심 분리하였다. ⑤ After centrifugation, the transparent supernatant was transferred to a new tube, and then 100 μL of isopropyl alcohol was added and carefully inverted (invert). The mixture was left at room temperature for 10 minutes and then centrifuged at 12,000 rpm at 4 ° C. for 10 minutes.
⑥ 상등액을 버리고 RNA 펠렛을 DEPC(diethyl pyrocarbonate)가 처리된 정제수로 희석한 75 부피%의 에탄올 200 uL를 넣어 펠렛을 세척해준 뒤 상등액을 버리고 RNA 펠렛을 실온 건조하였다.⑥ The supernatant was discarded, and the RNA pellet was diluted with DEPC (diethyl pyrocarbonate) -treated purified water and 200 μL of 75 vol% ethanol was added to wash the pellet. The supernatant was discarded and the RNA pellet was dried at room temperature.
⑦ 건조시킨 RNA 펠렛에 DEPC가 처리된 정제수 50 uL를 넣어 현탁시킨 뒤 55 내지 60℃에서 10분간 가열한다.7. Suspend 50 μL of purified DEPC-treated RNA pellet in the dried RNA pellet, and heat at 55 to 60 ° C for 10 minutes.
⑧ 그런 뒤, RNA를 260nm에서 흡광도를 통하여 정량하였다.⑧ Then, the RNA was quantified by absorbance at 260 nm.
정량값 구하는 식: 정량값=OD 값 * 희석배수 * 40 ug/mLQuantitative value formula: Quantitative value = OD value * Dilution factor * 40 ug / mL
(OD260=1은 40 ug/mL)(OD260 = 1 is 40 [mu] g / mL)
(4) cDNA합성은 PrimeScript 1st strand cDNA Synthesis Kit(TaKaRa, Cat. No 6110A)를 이용하였고 키트의 방법에 의해 실험을 수행하였다. PCR은 Taq polymerase Kit(TaKaRa, Cat. No R001A)를 사용하여 그 키트의 방법에 따라 수행하고 PCR장비(Biofree, Cat. No TC-96/G/H/(b)B)를 이용해 하기 표 2의 프라이머(이하 실험에서 사용된 모든 프라이머는 바이오니아(Daejeon, Korea)에서 주문 제작하였다)로 유전자를 증폭하였다. PCR에 의하여 생성된 산물은 1%의 아가로스 겔에서 전기영동하여 이미지 분석기(KOREALABTECH, Bundang, Korea; 제품 번호 DGS-200D)로 확인하고, 겔 기록 시스템(Gel documentation system)(KOREALABTECH, Bundang, Korea; 제품 번호 DGS-200D)와 이미지 J 프로그램(National Institutes of Health; 웹사이트[imagej.net]를 통해 입수)으로 분석하여 NF-κB의 발현양을 도 2에 나타내었다.(4) cDNA synthesis was carried out using the PrimeScript 1st strand cDNA Synthesis Kit (TaKaRa, Cat. No. 6110A). PCR was performed according to the kit method using a Taq polymerase kit (TaKaRa, Cat No R001A) and PCR was performed using the PCR equipment (Biofree, Cat. No. TC-96 / G / H / (All primers used in the following experiments were custom-made in Biona (Daejeon, Korea)). The PCR product was electrophoresed on 1% agarose gel and confirmed with an image analyzer (KOREALABTECH, Bundang, Korea; product number DGS-200D) and gel recording system (KOREALABTECH, Bundang, Korea ; Product number DGS-200D) and Image J program (available from the National Institutes of Health website [imagej.net]) and the amount of expression of NF-κB is shown in FIG.
Reverse: 5’-TTT ATG CCT ACA GCC TCC T-3’(서열번호 2)Forward: 5'-TCT CAG CAA TGT CAA CGA C-3 '(SEQ ID NO: 1)
Reverse: 5'-TTT ATG CCT ACA GCC TCC T-3 '(SEQ ID NO: 2)
실시예 1-2, 실시예 2-2, 실시예 3-2 실시예 4, 및 대조예를 처리한 후 NF-κB의 유전자 발현율은 하기 수학식 2를 이용하여 계산하였다.After the treatment of Examples 1-2, 2-2, and 3-2 and Example 4, the gene expression rate of NF-κB was calculated using the following equation (2).
[수학식 2]&Quot; (2) "
각 유전자의 발현율(%) = (시료 처리시 유전자 발현양/대조군의 유전자 발현 양) X 100Expression rate of each gene (%) = (amount of gene expression at the time of sample treatment / amount of gene expression in the control group)
도 2에 따르면 본 발명의 일측면에 따른 실시예 1-2(홍화 추출물), 실시예 2-2(타임 추출물), 실시예 3-2(타마린드 추출물) 및 실시예 4(홍화 추출물, 타임 추출물, 및 타마린드 추출물의 혼합물)의 조성물로 처리한 경우, UVB에 의한 손상으로 유도되는 NF-κB의 발현량이 감소되는 것을 확인할 수 있다. 특히 홍화 추출물, 타임 추출물, 타마린드 추출물을 모두 조합한 조성물(실시예 4)는 추출물 각각에 비하여 NF-κB의 발현을 더 저해하는 효과를 나타내었다.2 (Time Extract), Example 3-2 (Tamarind Extract), and Example 4 (Safflower Extract, Time Extract) according to one aspect of the present invention, Extract, and tamarind extract), the amount of NF-κB expression induced by UVB-induced damage is reduced. In particular, the composition comprising all of the safflower extract, time extract, and tamarind extract (Example 4) showed an effect of further inhibiting the expression of NF-κB in comparison with each of the extracts.
상기 결과를 통하여 본 발명의 일측면에 따른 조성물이 현저한 피부 항염 효과를 나타낸다는 점을 확인할 수 있다.From the above results, it can be seen that the composition according to one aspect of the present invention shows a remarkable skin anti-inflammatory effect.
[시험예 3] 식물 추출물의 피지 분비 억제 효과 평가[Test Example 3] Evaluation of the inhibitory effect of plant extract on sebum secretion
(1) 인간 각질형성세포인 HaCaT(GIBCO, 제품번호 HEKa(C-005-5C))세포를 6-웰 플레이트에 5×105 cell/well의 농도로 각각 분주한 후, 각 웰에 10부피%의 소태아혈청(GIBCO, 제품 번호 12483-020), 100 IU/ml의 페니실린(SIGMA, 제품 번호 M5655) 및 100μg/ml의 스트렙토마이신(SIGMA, 제품 번호 S9137)이 첨가된 DEME 배지(Wellgene, 제품번호 LM001-51)를 넣고 37℃, 5%의 CO2 하에서(이하 세포 배양시 동일한 조건) 2 일간 배양하였다.(1) Human keratinocytes HaCaT in (GIBCO, product number HEKa (C-005-5C)) cells in a 6-well plate, each dispensed at a concentration of 5 × 10 5 cell / well and then, 10 volume to each well (Wellgen, St. Louis, MO) supplemented with 100% fetal bovine serum (GIBCO, Cat. No. 12483-020), 100 IU / ml penicillin (SIGMA, Cat. No. M5655) and 100 ug / ml streptomycin (SIGMA, Cat. No. S9137) Product number LM001-51) was added and incubated for 2 days at 37 ° C under 5% CO 2 (the same conditions for cell culture).
(2) 배양된 HaCaT 세포를 PBS로 세척하고 동일한 DEME 배지로 교체하는 것과 함께 실시예 1-2, 실시예 3-2, 실시예 4, 및 대조예와 피지 분비 유도를 위한 디하이드로테스토스테론(Sigma, 제품 번호 D-073)을 함께 처리하여 37℃, 5%의 CO2 하에서 3 일간 배양하였다.(2) cultured HaCaT cells were washed with PBS and replaced with the same DEME medium, and the cells were treated with dihydrotestosterone (Sigma) for the induction of sebum secretion in Examples 1-2, 3-2, and 4, , Product No. D-073) were treated together and cultured at 37 占 폚 under 5% CO 2 for 3 days.
(3) 이렇게 배양된 세포에서 상기 시험예 2의 (3) 및 (4)의 방법에 따르되, 하기 표 3의 프라미어를 사용하여 SCD-1(stearoyl-CoA desaturase-1)의 발현량을 측정하였다.(3) The expression level of SCD-1 (stearoyl-CoA desaturase-1) was measured using the primers shown in Table 3 according to the methods of (3) and (4) Respectively.
Reverse: 5’-GCG GTA CTC ACT GGC AGA GT-3’ (서열번호 4)Forward: 5'-CCG GGA GAA TAT CCT GGT TT-3 '(SEQ ID NO: 3)
Reverse: 5'-GCG GTA CTC ACT GGC AGA GT-3 '(SEQ ID NO: 4)
그리고 상기 수학식 2를 이용하여 계산된 SCD-1의 발현율을 도 3에 나타내었다. FIG. 3 shows the expression level of SCD-1 calculated using the above equation (2).
도 3의 결과에 따르면 본 발명의 일측면에 따른 실시예 1-2(홍화 추출물), 실시예 3-2(타마린드 추출물), 및 실시예 4(홍화 추출물, 타임 추출물, 및 타마린드 추출물의 혼합물)의 조성물로 처리한 경우 피지 분비와 관련된 SCD-1의 발현을 저해하는 것을 확인할 수 있다. 특히 홍화 추출물, 타임 추출물, 타마린드 추출물을 모두 조합한 조성물(실시예 4)는 추출물 각각에 비하여 SCD-1 유전자의 발현을 더 저해하는 효과를 나타내었다.According to the results shown in FIG. 3, the extract of Example 1-2 (safflower extract), Example 3-2 (tamarind extract), and Example 4 (safflower extract, time extract, and tamarind extract) according to one aspect of the present invention Mixture) inhibits the expression of SCD-1 associated with sebum secretion. In particular, the composition comprising both safflower extract, time extract and tamarind extract (Example 4) showed an effect of further inhibiting the expression of SCD-1 gene in comparison with each of extracts.
이러한 결과를 통하여 본 발명의 일측면에 따른 조성물이 현저하게 우수한 피지 분비 억제 효과를 나타낸다는 점을 확인할 수 있다.From these results, it can be seen that the composition according to one aspect of the present invention shows remarkably excellent sebum secretion suppressing effect.
그러므로, 상기 시험예 2 및 3의 결과에 따르면 본 발명의 일측면에 따른 조성물은 현저하게 우수한 피부 항염 및 피부 피지 분비 억제 효과를 가지며, 그로 인해 피부 여드름을 현저하게 개선할 수 있다는 점을 확인할 수 있다.Therefore, according to the results of Test Examples 2 and 3, it can be seen that the composition according to one aspect of the present invention has remarkably excellent skin anti-inflammation and suppression of secretion of skin sebum, thereby remarkably improving skin acne have.
본 발명의 일 측면에 따른 조성물의 제형예를 아래에서 설명하나, 이외의 다른 여러 가지 제형으로도 응용 가능하며, 이는 본 명세서를 제한하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Formulation examples of the composition according to one aspect of the present invention are described below, but may be applied to various other formulations, which are not intended to limit the specification, but merely to illustrate them.
[제형예 1] 유연화장수(스킨로션)[Formulation Example 1] Softening lotion (skin lotion)
하기 표 4에 기재된 조성에 따라 통상적인 방법으로 유연화장수를 제조하였다.The softening longevity was prepared by a conventional method according to the composition shown in Table 4 below.
[제형예 2] 영양화장수(밀크로션)[Formulation Example 2] Nutritional lotion (Milk lotion)
하기 표 5에 기재된 조성에 따라 통상적인 방법으로 영양화장수를 제조하였다.Nutrition lotion was prepared according to the conventional method according to the composition shown in Table 5 below.
[제형예 3] 영양크림[Formulation Example 3] Nourishing cream
하기 표 6에 기재된 조성에 따라 통상적인 방법으로 영양크림을 제조하였다.The nutritional creams were prepared according to the compositions shown in Table 6 below in a conventional manner.
[제형예 4] 마사지 크림[Formulation Example 4] Massage cream
하기 표 7에 기재된 조성에 따라 통상적인 방법으로 마사지 크림을 제조하였다.Massage creams were prepared in a conventional manner according to the composition shown in Table 7 below.
[제형예 5] 팩[Formulation Example 5] Pack
하기 표 8에 기재된 조성에 따라 통상적인 방법으로 팩을 제조하였다.The packs were prepared in a conventional manner according to the composition shown in Table 8 below.
이상으로 본 명세서의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 명세서의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 명세서의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Having described specific portions of the disclosure in detail, those skilled in the art will appreciate that these specific embodiments are merely exemplary and are not intended to limit the scope of the disclosure. Accordingly, the actual scope of the disclosure will be defined by the appended claims and their equivalents.
<110> Yuhan-Kimberly, Limited
<120> COMPOSITION FOR ANTI-INFLAMMATION, INHIBITING SECRETION OF SEBUM, OR TREATING ACNE ON THE SKIN COMPRISING PLANT EXTRACT
<130> KC171053
<160> 4
<170> KoPatentIn 3.0
<210> 1
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer of NF-kappa B
<400> 1
tctcagcaat gtcaacgac 19
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer of NF-kappa B
<400> 2
tttatgccta cagcctcct 19
<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer of SCD-1
<400> 3
ccgggagaat atcctggttt 20
<210> 4
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer of SCD-1
<400> 4
gcggtactca ctggcagagt 20
<110> Yuhan-Kimberly, Limited
<120> COMPOSITION FOR ANTI-INFLAMMATION, INHIBITING SECRETION OF SEBUM, OR TREATING ACNE ON THE SKIN COMPRISING PLANT EXTRACT
<130> KC171053
<160> 4
<170> KoPatentin 3.0
<210> 1
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer of NF-kappa B
<400> 1
tctcagcaat gtcaacgac 19
<210> 2
<211> 19
<212> DNA
<213> Artificial Sequence
<220>
<223> Reverse primer of NF-kappa B
<400> 2
tttatgccta cagcctcct 19
<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> Forward primer of SCD-1
<400> 3
Claims (12)
상기 조성물은 홍화 추출물, 타임 추출물 및 타마린드 추출물 중의 2 이상의 조합을 유효성분으로 포함하는 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
Wherein the composition comprises at least two of a safflower extract, a time extract and a tamarind extract as an active ingredient, the composition being for inhibiting the secretion of skin sebum or for improving skin acne.
조성물의 총 부피에 대하여 추출물의 총 함량은 0.0001 부피% 이상 5 부피% 미만인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
Wherein the total content of the extract relative to the total volume of the composition is from 0.0001% by volume to less than 5% by volume, the composition being for inhibiting skin sebum secretion or improving skin acne.
홍화 추출물은 홍화 초본의 종자 추출물인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
The safflower extract is a seed extract of safflower herb, a composition for treating skin inflammation, inhibiting secretion of skin sebum or improving skin acne.
타임 추출물은 타임 초본의 잎, 줄기 및 이들의 조합으로 구성된 군으로부터 선택된 하나 이상의 추출물인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
Wherein the time extract is at least one extract selected from the group consisting of leaves, stems, and combinations thereof, the composition being for skin anti-inflammation, for suppressing secretion of skin sebum or for improving skin acne.
타마린드 추출물은 타마린드 목본의 종자 추출물인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
The tamarind extract is a seed extract of tamarind wood, a composition for skin anti-inflammation, inhibiting the secretion of skin sebum, or improving skin acne.
상기 조성물은 항산화제, 보존제, 흡수제, 각질제거제, 증점제, 선크림제제, 유화제, 계면활성제, 향료, 소취제, 안정화제, 피부 보호제, 및 pH 조절제 중 하나 이상을 더 포함하는 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
Wherein the composition further comprises at least one of an antioxidant, a preservative, an absorbent, an exfoliation agent, a thickener, a sunscreen agent, an emulsifier, a surfactant, a perfume, a deodorant, a stabilizer, a skin protective agent, Or skin acne.
상기 조성물은 홍화 추출물, 타임 추출물 및 타마린드 추출물의 조합을 유효성분으로 포함하되 그 부피비가 1~9:1~9:1~9 인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.The method according to claim 1,
Wherein the composition comprises a combination of safflower extract, time extract and tamarind extract as an active ingredient, wherein the volume ratio is 1 to 9: 1 to 9: 1 to 9, for the suppression of skin sebum secretion or for improving skin acne.
상기 조성물은 화장품, 피부 외용제, 또는 위생용품에 사용되는 것을 특징으로 하는 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.9. The method according to any one of claims 1 to 8,
Wherein the composition is used in a cosmetic, an external preparation for skin, or a sanitary article, wherein the composition is for inhibiting skin sebum secretion or for improving skin acne.
상기 화장품은 기초 화장품, 메이크업 화장품, 헤어케어 화장품, 얼굴 케어 화장품, 및 바디케어 화장품으로 구성된 군으로부터 선택된 어느 하나인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.10. The method of claim 9,
Wherein the cosmetic composition is any one selected from the group consisting of basic cosmetics, makeup cosmetics, hair care cosmetics, facial care cosmetics, and body care cosmetics, the composition being for inhibiting the secretion of skin sebum or improving skin acne.
상기 피부 외용제는 연고제, 로션제, 스프레이제, 패취제, 크림제, 산제, 현탁제, 및 겔제로 구성된 군으로부터 선택된 어느 하나인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.10. The method of claim 9,
Wherein the external preparation for skin is any one selected from the group consisting of an ointment, a lotion, a spray, a patch, a cream, a powder, a suspension, and a gel, wherein the composition is for inhibiting skin sebum secretion or for improving skin acne.
상기 위생용품은 물티슈, 티슈, 기저귀, 생리대, 위생 와이프, 습윤 와이프, 클리닝 와이프, 훼이셜 와이프, 스킨케어 와이프, 및 지한제 와이프로 구성된 군으로부터 선택된 어느 하나인 피부 항염, 피부 피지 분비 억제용 또는 피부 여드름 개선용 조성물.10. The method of claim 9,
The sanitary product may be any one selected from the group consisting of a wipe, a tissue, a diaper, a sanitary napkin, a sanitary wipe, a wet wipe, a cleaning wipe, a facial wipe, a skin care wipe, / RTI >
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170106280A KR102068194B1 (en) | 2017-08-22 | 2017-08-22 | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170106280A KR102068194B1 (en) | 2017-08-22 | 2017-08-22 | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190021114A true KR20190021114A (en) | 2019-03-05 |
| KR102068194B1 KR102068194B1 (en) | 2020-01-20 |
Family
ID=65760548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170106280A Active KR102068194B1 (en) | 2017-08-22 | 2017-08-22 | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102068194B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200120556A (en) * | 2019-04-12 | 2020-10-21 | 이연제약주식회사 | Composition for improving, preventing or treating skin disease comprising Thymus plant extract |
| KR102542555B1 (en) * | 2022-09-07 | 2023-06-15 | (주)엔비바이오컴퍼니 | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin |
| WO2025112964A1 (en) * | 2023-11-29 | 2025-06-05 | 广东丸美生物技术股份有限公司 | Acne removal and repair composition containing recombinant collagen and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003063980A (en) * | 2001-08-28 | 2003-03-05 | Noevir Co Ltd | Rantes-production inhibitor |
| KR100955389B1 (en) | 2009-06-29 | 2010-04-29 | (주)바이오에프디엔씨 | Cosmetic composition for pore-minimizing and inhibition of sebum secretion containing natural materials |
| KR20160085011A (en) * | 2015-01-07 | 2016-07-15 | 코스맥스 주식회사 | Cosmetic composition for alleviating sebum secretion comprising Carthamus tinctorius extract or mixture extract of Carthamus tinctorius and Areca catechu |
-
2017
- 2017-08-22 KR KR1020170106280A patent/KR102068194B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003063980A (en) * | 2001-08-28 | 2003-03-05 | Noevir Co Ltd | Rantes-production inhibitor |
| KR100955389B1 (en) | 2009-06-29 | 2010-04-29 | (주)바이오에프디엔씨 | Cosmetic composition for pore-minimizing and inhibition of sebum secretion containing natural materials |
| KR20160085011A (en) * | 2015-01-07 | 2016-07-15 | 코스맥스 주식회사 | Cosmetic composition for alleviating sebum secretion comprising Carthamus tinctorius extract or mixture extract of Carthamus tinctorius and Areca catechu |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200120556A (en) * | 2019-04-12 | 2020-10-21 | 이연제약주식회사 | Composition for improving, preventing or treating skin disease comprising Thymus plant extract |
| KR102542555B1 (en) * | 2022-09-07 | 2023-06-15 | (주)엔비바이오컴퍼니 | Cosmetic composition for anti-inflammatory and anti-acne comprising vegetable mucin |
| WO2025112964A1 (en) * | 2023-11-29 | 2025-06-05 | 广东丸美生物技术股份有限公司 | Acne removal and repair composition containing recombinant collagen and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102068194B1 (en) | 2020-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8101214B2 (en) | Composition for skin external application containing complex of herbal extracts | |
| KR100755427B1 (en) | Cosmetic composition containing green tea seed oil having a skin elasticity promoting effect. | |
| KR101490762B1 (en) | Cosmetic composition comprising the polysaccharide of Hibiscus esculentus as active ingredient | |
| WO2001026670A1 (en) | Skin-care agents, skin antiaging agents, whitening agents and external skin preparations | |
| KR101885195B1 (en) | Cosmetic Composition with Fermentative Extract of Osmanthus fragrans | |
| KR102367528B1 (en) | Cosmetic composition comprising seaweed extracts | |
| KR101634668B1 (en) | Cosmetic composition comprising fermented extract of mistletoe for anti-oxidation or whitening | |
| KR20100130878A (en) | Cosmetic composition containing plant extract | |
| KR102400179B1 (en) | Cosmetic composition antimicroboal, antioxidation, whitening or anti-inflammation comprising artemisia capillaris thunberg and olive extract | |
| KR20170019830A (en) | Composition for the natural surfactant and cosmetic composition containing Saponaria officinalis, Yucca Schidigera and Quillaia saponaria MOLINA | |
| KR102068194B1 (en) | Composition for anti-inflammation, inhibiting secretion of sebum, or treating acne on the skin comprising plant extract | |
| KR102085052B1 (en) | Composition for anti-inflammatory or moisturizing on skin comprising plant extract | |
| KR102257448B1 (en) | Cosmetic composition containing black kelp | |
| KR101587077B1 (en) | Composition containing fermentated opuntia humifusa showing biological activity of skin | |
| JP2021004214A (en) | Combinational fermented product | |
| KR20150116504A (en) | A cosmetics composition containing tea tree and solt | |
| KR102168601B1 (en) | Skincare composition comprising safflower Ferment Extract fermented by Phellinus linteus | |
| KR100946584B1 (en) | Cosmetic composition for astringent and skin irritation containing fruit extract and Blue Lotus extract | |
| JP5155543B2 (en) | Endothelin-1 production inhibitor, hexosaminidase release inhibitor, anti-inflammatory / whitening skin preparation, endothelin-1 production inhibition method, and hexosaminidase release inhibition method | |
| KR20200073523A (en) | Cosmetic Composition for Improving Skin Wrinkle Contaning the Extract of Lithospermum Erythrorhizon | |
| KR102672765B1 (en) | Cosmetic composition for UV protection with excellent skin moisturizing effect and feeling of use | |
| KR102477182B1 (en) | Cosmetic composition for improving skin inflammation and wrinkles comprising Aaronia pomace extract | |
| KR102718114B1 (en) | Composition for inhibiting body odor, serum secretion, and dandruff comprising Lagerstroemia indica extracts as an active ingredient | |
| KR20130034720A (en) | Cosmetic composition comprising the extract of viburnum odoratissimum var. awabuki as active ingredient | |
| KR20120076168A (en) | Skin antiaging agent and composition for skin antiaging comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170822 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180706 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20170822 Comment text: Patent Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190730 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20191230 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200114 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200115 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20230112 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240110 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250114 Start annual number: 6 End annual number: 6 |